FDA Penalizes Mammography Center

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 10
Volume 7
Issue 10

ROCKVILLE, Md--A Chicago mammography facility, known as CMI, has agreed to pay a $30,000 fine and to cease operating in the mammography field for 5 years. The FDA had accused it of performing mammography exams without

ROCKVILLE, Md--A Chicago mammography facility, known as CMI, has agreed to pay a $30,000 fine and to cease operating in the mammography field for 5 years. The FDA had accused it of performing mammography exams without accreditation, a violation of the Mammography Quality Standards Act of 1992. Both CMI and its president, Thomas E. Miller, will remove themselves from the mammography field and jointly pay $25,000. The facility’s supervisory radiologist will pay $5,000. The case is the first time a mammography facility has been required to pay a civil money penalty under the Act.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.